Rakuten Securities Inc. Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Rakuten Securities Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,719 shares of the company’s stock, valued at approximately $114,000.

Other institutional investors have also recently modified their holdings of the company. Quest Partners LLC increased its position in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. Stonekeep Investments LLC increased its holdings in Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares in the last quarter. Principal Securities Inc. lifted its holdings in Hims & Hers Health by 48.2% during the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Hims & Hers Health by 1.9% in the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock valued at $1,271,000 after purchasing an additional 1,002 shares during the period. Finally, Cadent Capital Advisors LLC raised its position in shares of Hims & Hers Health by 1.5% during the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after purchasing an additional 1,060 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on HIMS. Citigroup reiterated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Truist Financial increased their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $37.23.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $34.00 on Thursday. The company’s 50-day moving average is $38.23 and its two-hundred day moving average is $27.90. The firm has a market capitalization of $7.55 billion, a price-to-earnings ratio of 77.27 and a beta of 1.37. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $9,319,952.14. The trade was a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 969,191 shares of company stock worth $34,005,375. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.